FULL BOARD COMMITTEE REVIEW
Subject to a review by the board members at a scheduled meeting, with PI present, subject to meeting dates / deadlines, review of scientific merit, biostatistical plan analysis, and appropriate allocation of resources (10 business days)

All interventional studies in which individuals are assigned prospectively by an investigator based on a protocol to receive specific interventions. The participants may receive diagnostic, treatment, behavioral, or other types of interventions. The assignment of the intervention may or may not be random. The participants are followed and biomedical and/or health outcomes are assessed.

SUBMIT TO IRB

PRMC Approval

ADMINISTRATIVE REVIEW
Expedited review by an executive sub-committee as received. Not subject to meeting dates / deadlines (5 business days)

If your Protocol is prospective, Cancer related & DMG approval obtained

• National Cooperative group studies
• Externally Peer Reviewed Trials
• Any peer reviewed study supported by an NIH mechanism (ie: ROIs, U01s, U10s, POIs, and P50s, etc.)
• Observational studies that focus on cancer patients and healthy populations and involve no prospective intervention or alteration in the status of the participants and assess biomedical and/or health outcome(s) in pre defined groups of participants.
• Ancillary or Correlative studies
• Laboratory based studies that are prospectively collecting consent and using specimens to assess cancer risk, clinical outcomes, response to therapies

Updated January 2020